Breaking News Headlines Today | Ground News

New Year’s Sale — Build a balanced news diet with 40% off Vantage

Pharmaceutical-technology.com image

News from pharmaceutical-technology.com

Ground News rates Pharmaceutical-technology.com’s media bias as unknown. Ground News is unable to assign a bias rating and does not have ratings available from Ad Fontes Media, AllSides, and Media Bias/Fact Check.

Pharmaceutical-technology.com’s factuality rating is Unknown. Ground News calculates this rating using a combination of the fact and reliability ratings from Ad Fontes Media and Media Bias/Fact Check.

Information about Pharmaceutical-technology.com

Where is Pharmaceutical-technology.com located?Pharmaceutical-technology.com's Website

Media Bias Ratings

Do you disagree?

Edit bias

Learn more about Media Bias Ratings.

Factuality

Learn more about Factuality Ratings

Reveal Factuality Ratings by upgrading to a Premium account.

Tap Upgrade to explore subscription options to meet all your reading needs.

Ownership

Learn more about Ownership categories

Reveal Ownership Data by upgrading to a Vantage account.

Tap Upgrade to explore subscription options to meet all your reading needs.

Top Pharmaceutical-technology.com News

U.S. overhauls childhood vaccine schedule, recommends fewer shots — REUTERS / ixx511

Health · United States

U.S. overhauls childhood vaccine schedule, recommends fewer shots

54% Center coverage: 201 sources

The United States on Monday said it was revising its childhood immunization schedule to recommend four fewer vaccines, a move it said aligns the country with other developed nations while also advancing one of Health Secretary Robert F. Kennedy Jr.'s long-term goals.See the Story

Insilico Medicine Announce US$888 Million Multi-Year Collaboration with Servier for Drug Discovery and Development in Oncology

Cancer · Cambridge

Insilico Medicine Announce US$888 Million Multi-Year Collaboration with Servier for Drug Discovery and Development in Oncology

66% Center coverage: 29 sources

Insilico Medicine achieved an R&D collaboration with Servier valued at up to US$888 million, focused on discovering and developing innovative oncology therapies, by combining Insilico's AI-driven drug discovery platforms with Servier's global expertise in cancer drug development. Under the terms…See the Story

GSK's Chronic Hepatitis B Therapy Shows Promise in Key ...

Carlsbad, California · Carlsbad

GSK's Chronic Hepatitis B Therapy Shows Promise in Key ...

86% Center coverage: 7 sources

GSK’s bepirovirsen met the main goal of two Phase 3 studies, achieving functional cure rates for patients with chronic hepatitis B infection after six months of treatment. This antisense oligonucleotide therapy could provide a treatment alternative to antiviral drugs that patients must take for life. The post GSK Gets Closer to Bringing Patients a Functional Cure for Chronic Hepatitis B appeared first on MedCity News.See the Story

Breaking News Topics Related to Pharmaceutical-technology.com